Page last updated: 2024-09-05

lenalidomide and Intraocular Lymphoma

lenalidomide has been researched along with Intraocular Lymphoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beauchesne, P; Cassoux, N; Chevrier, M; Chinot, O; Choquet, S; Ghesquieres, H; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Laadhari, M; Le Garff-Tavernier, M; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Savignoni, A; Schmitt, A; Soumelis, V; Soussain, C; Touitou, V; Turbiez, I	1
Damato, B; Formaker, P; Geng, H; Hwang, J; Mannis, G; Munster, PN; Rubenstein, JL; Vu, K	1
Ghesquieres, H; Soussain, C	1

Trials

1 trial(s) available for lenalidomide and Intraocular Lymphoma

Article	Year
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Intention to Treat Analysis; Intraocular Lymphoma; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Proof of Concept Study; Prospective Studies; Remission Induction; Rituximab	2019

Article

Year

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and

Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Intention to Treat Analysis; Intraocular Lymphoma; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Proof of Concept Study; Prospective Studies; Remission Induction; Rituximab

2019

Other Studies

2 other study(ies) available for lenalidomide and Intraocular Lymphoma

Article	Year
Maintenance lenalidomide in primary CNS lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 08-01, Volume: 30, Issue:8 Topics: Humans; Intraocular Lymphoma; Lenalidomide; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Rituximab	2019
Reply to the letter to the editor 'Maintenance lenalidomide in primary CNS lymphoma' by Rubenstein et al. Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 08-01, Volume: 30, Issue:8 Topics: Humans; Intraocular Lymphoma; Lenalidomide; Lymphoma; Prospective Studies; Rituximab	2019